Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay.
Chagas disease, caused by the protozoan intracellular parasite Trypanosoma cruzi, is a highly neglected tropical disease, causing significant morbidity and mortality in central and south America. Current treatments are inadequate, and recent clinical trials of drugs inhibiting CYP51 have failed, exp...
Guardado en:
Autores principales: | Nina Svensen, Susan Wyllie, David W Gray, Manu De Rycker |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0428e734a42f4d65a9fe295ff74ee419 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box.
por: Juan Cantizani, et al.
Publicado: (2021) -
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
por: J Mark F Gardner, et al.
Publicado: (2021) -
The costs of preventing and treating chagas disease in Colombia.
por: Marianela Castillo-Riquelme, et al.
Publicado: (2008) -
A novel substrate for arrhythmias in Chagas disease.
por: Artur Santos-Miranda, et al.
Publicado: (2021) -
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
por: Maha-Hamadien Abdulla, et al.
Publicado: (2009)